European Patent Granted for ZyVersa Therapeutics’ Lead Asset, Cholesterol Efflux Mediator™ VAR 200 for Use in Patients with Diabetic Nephropathy/Diabetic Kidney Disease

<p>Cholesterol Efflux Mediator™ VAR 200 is in phase 2a development to reduce renal cholesterol and lipid accumulation that damages the kidneys’ filtration system in patients with glomerular diseases, including diabetic kidney disease, focal segmental glomerulosclerosis, and Alport syndrome WESTON, Fla., July 07, 2023 (GLOBE NEWSWIRE) — ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA, or “ZyVersa”), a clinical stage […]</p>
<p>The post <a rel="nofollow" href="https://forextv.com/top-news/european-patent-granted-for-zyversa-therapeutics-lead-asset-cholesterol-efflux-mediator-var-200-for-use-in-patients-with-diabetic-nephropathy-diabetic-kidney-disease/">European Patent Granted for ZyVersa Therapeutics’ Lead Asset, Cholesterol Efflux Mediator™ VAR 200 for Use in Patients with Diabetic Nephropathy/Diabetic Kidney Disease</a> appeared first on <a rel="nofollow" href="https://forextv.com">ForexTV</a>.</p>